Jean M. Franchi Sells 3,136 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean M. Franchi sold 3,136 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $171,162.88. Following the completion of the transaction, the chief financial officer now owns 69,530 shares in the company, valued at $3,794,947.40. This trade represents a 4.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Disc Medicine Stock Up 0.3 %

Shares of NASDAQ:IRON opened at $54.52 on Friday. Disc Medicine, Inc. has a twelve month low of $25.60 and a twelve month high of $77.60. The stock’s 50 day moving average is $59.05 and its 200-day moving average is $55.10. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -13.70 and a beta of 0.73.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. HC Wainwright reissued a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday, January 21st. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a research report on Tuesday, November 5th. Wedbush reiterated an “outperform” rating and issued a $90.00 target price (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, Scotiabank increased their price target on Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Wednesday, January 22nd. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $88.90.

Institutional Trading of Disc Medicine

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its stake in shares of Disc Medicine by 358.7% in the fourth quarter. FMR LLC now owns 1,866,248 shares of the company’s stock valued at $118,320,000 after buying an additional 1,459,434 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Disc Medicine by 62.4% in the 4th quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after acquiring an additional 467,988 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Disc Medicine by 23.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock valued at $88,421,000 after acquiring an additional 262,690 shares in the last quarter. State Street Corp boosted its stake in Disc Medicine by 39.7% during the 3rd quarter. State Street Corp now owns 827,910 shares of the company’s stock valued at $40,683,000 after purchasing an additional 235,115 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Disc Medicine during the 4th quarter worth approximately $5,579,000. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.